



ArcaScience

Seek less, discover better

STUDIES SERIE:

EXPERTISE MAPPER

Timeframe:

**from 01/01/2021
to 06/06/2024**

Zone of interest:

None

Medical domain:

None

Pathology:

Dermatomyositis



**2024
Edition**

Affiliation and Expertise Mapping: Enhancing Collaboration in Drug Projects

Expertise Mapping Report

Date : November 22nd, 2024

Table of contents

Part 1: Institutional Affiliations and Collaborations

Part 2: Key Contributors Analysis

Key Contributors Report Preface

Developed by the ArcaScience team, this report unlocks a strategic advantage in area of Dermatomyositis research. It unveils the top institutions and leading experts who hold the key to successful recruitment and scientific collaboration.

Within, you'll discover:

- **Global/Local Affiliations in Dermatomyositis Research** : Identify the top institutions driving the field, globally. Analyze their clinical trial (CT) activity, including recruitment rates, patient enrollment, and trial durations.
- **Key Contributors for Dermatomyositis** : Pinpoint the top Key Contributors (globally) with the combined power of their clinical trial involvement and proven scientific contributions. Gain access to detailed profiles of each Key Contributor, including affiliations, publications, and relevant expertise.

The data presented in this report is extracted from ClinicalTrials.gov and Pubmed (Medline/PMC), including all published clinical trials and articles, from January 1st, 2021 to June 6th, 2024, concerning Dermatomyositis, for a total number of 27 clinical trials and 1956 articles.

More in detail, at the global scale, 2699 affiliations were cited to have contributed within the area of Dermatomyositis. 2752 investigators and/or first or last authors were cited to have contributed within the area of Dermatomyositis.

To obtain comprehensive information about the Key Contributors and their affiliation(s), you can refer to the CSVs provided. If you require any clarification or assistance in interpreting the data, the ArcaScience Team is readily available to help you.

Part 1: Institutional Affiliations and Collaborations

Potential Recruiting Opportunities

Global Insights : Top Affiliations

 **Mayo Clinic, Department of Dermatology, Scottsdale, United States** : 3 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

Study of M5049 in DM and PM Participants (NEPTUNIA)

- **Sponsor(s)** : EMD Serono Research & Development Institute, Inc., Industry
- **Collaborator(s)** : Merck KGaA, Darmstadt, Germany, Industry
- **Drugs Investigated** : Enpatoran
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 40 (not exclusively this site)
- **Duration of Trial** : 22 months

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : Anti-Beta Interferon (PF-06823859)
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)
- **Duration of Trial** : 23 months

 **University of Kansas Medical Center, Department of Cardiology, Kansas City, United States** : 3 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

Study of M5049 in DM and PM Participants (NEPTUNIA)

- **Sponsor(s)** : EMD Serono Research & Development Institute, Inc., Industry
- **Collaborator(s)** : Merck KGaA, Darmstadt, Germany, Industry
- **Drugs Investigated** : Enpatoran
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 40 (not exclusively this site)
- **Duration of Trial** : 22 months

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : Anti-Beta Interferon (PF-06823859)
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)
- **Duration of Trial** : 23 months

 The First Affiliated Hospital of Nanjing Medical University, Department of Rheumatology, Nanjing, Moldova

: 3 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

- **Sponsor(s)** : The First Affiliated Hospital with Nanjing Medical University, Other
- **Drugs Investigated** : dual-therapy, triple therapy
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 120 (not exclusively this site)
- **Duration of Trial** : 35 months

Recent but Not Recruiting Clinical Trials

Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis

- **Sponsor(s)** : The First Affiliated Hospital with Nanjing Medical University, Other
- **Collaborator(s)** : National Natural Science Foundation of China, Other
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 1000 (not exclusively this site)
- **Duration of Trial** : 30 months

An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis

- **Sponsor(s)** : The First Affiliated Hospital with Nanjing Medical University, Other
- **Collaborator(s)** : National Natural Science Foundation of China, Other
- **Drugs Investigated** : Abatacept
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 20 (not exclusively this site)
- **Duration of Trial** : 17 months

 Brigham and Women's Hospital, Department of Dermatology, CTH, Brigham, United Kingdom : 3 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

- **Sponsor(s)** : National Institute of Allergy and Infectious Diseases (NIAID), NIH
- **Collaborator(s)** : Autoimmunity Centers of Excellence, Other
- **Investigator(s)** : Natasha Mckerran, Virginia Pascual, Stacy P Ardoin, Dinesh Khanna, Tracey Wright, Judith A James, Meggan C Mackay
- **Drugs Investigated** : Continue IS (MTX), mAbs targeting CD19 or CD20, SARS-CoV-2 RNA vaccine, Withhold IS (MTX), MPA, Continue IS (MMF or MPA), anti-BAFF mAb, mycophenolate mofetil, Sanofi-GSK COVID-19 Vaccine, Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (B cell depletion therapy), JNJ-78436735, mycophenolic acid, Continue IS (B cell depletion therapy), COVID-19 vaccine, immunosuppressive medication, methotrexate, Withhold IS (MMF or MPA), Elasmolan, Bivalent, MTX, COVID-19 vaccine and Bivalent, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, Ad26.COV2.S, Tozinameran, MMF
- **Population Investigated** : Senior Adults or Elders (65+ years old), Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 257 (not exclusively this site)
- **Duration of Trial** : 31 months

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : Anti-Beta Interferon (PF-06823859)
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)
- **Duration of Trial** : 23 months

 Cleveland Clinic, Department of Cardiovascular Medicine, Ophthalmology Department, Cleveland, United Kingdom

: 3 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

- **Sponsor(s)** : National Institute of Allergy and Infectious Diseases (NIAID), NIH
- **Collaborator(s)** : Autoimmunity Centers of Excellence, Other
- **Investigator(s)** : Natasha Mckerran, Virginia Pascual, Stacy P Ardoin, Dinesh Khanna, Tracey Wright, Judith A James, Meggan C Mackay
- **Drugs Investigated** : Continue IS (MTX), mAbs targeting CD19 or CD20, SARS-CoV-2 RNA vaccine, Withhold IS (MTX), MPA, Continue IS (MMF or MPA), anti-BAFF mAb, mycophenolate mofetil, Sanofi-GSK COVID-19 Vaccine, Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (B cell depletion therapy), JNJ-78436735, mycophenolic acid, Continue IS (B cell depletion therapy), COVID-19 vaccine, immunosuppressive medication, methotrexate, Withhold IS (MMF or MPA), Elasmolan, Bivalent, MTX, COVID-19 vaccine and Bivalent, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, Ad26.COV2.S, Tozinameran, MMF
- **Population Investigated** : Senior Adults or Elders (65+ years old), Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 257 (not exclusively this site)
- **Duration of Trial** : 31 months

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : Anti-Beta Interferon (PF-06823859)
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)

- **Duration of Trial** : 23 months

 **Azienda Ospedaliero-Universitaria Policlinico GRodolico-San Marco Di Catania, Catania, Italy** : 2 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

Study of M5049 in DM and PM Participants (NEPTUNIA)

- **Sponsor(s)** : EMD Serono Research & Development Institute, Inc., Industry
- **Collaborator(s)** : Merck KGaA, Darmstadt, Germany, Industry
- **Drugs Investigated** : Enpatoran
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 40 (not exclusively this site)
- **Duration of Trial** : 22 months

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

No recent but Not Recruiting Clinical Trials involving this site

 **CHUAC-Complejo Hospitalario Universitario A Coruña, Abteilung Dermatologie, A Coruna, Spain** : 2 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

Study of M5049 in DM and PM Participants (NEPTUNIA)

- **Sponsor(s)** : EMD Serono Research & Development Institute, Inc., Industry
- **Collaborator(s)** : Merck KGaA, Darmstadt, Germany, Industry
- **Drugs Investigated** : Enpatoran
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 40 (not exclusively this site)
- **Duration of Trial** : 22 months

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]


- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16-64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

No recent but Not Recruiting Clinical Trials involving this site

 **Seoul National University Hospital, Department of Internal Medicine, Division of Rheumatology, Seoul, South Korea** : 2 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] 

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16–64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis 

- **Sponsor(s)** : Paeon Biotechnology Inc., Industry
- **Investigator(s)** : Hyunsook Kim, Eunyong Lee, Daehyun Yoo
- **Drugs Investigated** : PN-101
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16–64 years old)
- **Number of Patients Enrolled** : 9 (not exclusively this site)
- **Duration of Trial** : 21 months

 **Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany** : 2 Clinical Trials

Main Key Contributors

Georg Schett , Professor

Main Recruiting Clinical Trials

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] 

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16–64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease 

- **Sponsor(s)** : University of Erlangen–Nürnberg Medical School, Other
- **Investigator(s)** : Georg Schett
- **Drugs Investigated** : anti-CD19 CAR T cell therapy
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16–64 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)
- **Duration of Trial** : 34 months

No recent but Not Recruiting Clinical Trials involving this site

 **Pfizer, Worldwide Research and Development, Cambridge, United Kingdom** : 2 Clinical Trials

No Associated Key Contributors

Main Recruiting Clinical Trials

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] 

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : PF-06823859
- **Population Investigated** : Senior Adults or Elders (65+ years old), Adults (16–64 years old)
- **Number of Patients Enrolled** : 270 (not exclusively this site)
- **Duration of Trial** : 38 months

Recent but Not Recruiting Clinical Trials

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

- **Sponsor(s)** : Pfizer, Industry
- **Drugs Investigated** : Anti-Beta Interferon (PF-06823859)
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old) , Middle-Old (75-84 years old)
- **Number of Patients Enrolled** : 24 (not exclusively this site)
- **Duration of Trial** : 23 months

Part 2: Key Contributors Analysis

Potential Scientific Advisory Board Members and Recruiters

Global Insights : Top Key Contributors for Clinical Trials

Linrong He

Expert Profile



- **Affiliations :**
 - The Second Affiliated Hospital of Xi'an Jiaotong University, Department of Dermatology, Xi an, China
 - Key Laboratory of Myositis, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, Beijing, China
- **Associated Keywords :** Interstitial Lung Disease, Prognosis, Tofacitinib, S100A8, Immunofluorescence, Anti-Mda5 Antibody, Infection, Bronchoscopy, Differentially Expressed Genes, Microarray, Janus Kinase Inhibitors

Recent Experience

- **Related Drugs :** Tofacitinib, JAK Inhibitor
- **Related Conditions :** Lupus Nephritis, Dermatomyositis
- **Population Investigated :** Adults (16-64 years old), Senior Adults or Elders: Young-Old (65-74 years old)

1 related Clinical Trial

- **July 15th, 2021 :** The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

2 related PMC/Medline publications

Yves Allenbach

Expert Profile



- **Position :** MD
- **Affiliations :**
 - Pitie-Salpêtrière hospital, APHP, Paris, France
 - Sorbonne Université, Department of Internal Medicine and Clinical Immunology, Paris, France
 - Pitie Salpetriere Hospital, Sorbonne University, Department of Internal Medicine and Clinical Immunology, Paris, France
 - INSERM, Center of Research in Myology UMRS 974, Sorbonne Université, Paris, France
- **Contacts :** yves.allenbach@aphp.fr
- **Associated Keywords :** Steroid Sparing, Muscle, Myostatin, Ultra Sound Imaging, Therapy, Interferon, Dermatomyositis, Virus, DM, Interstitial Lung Disease, Small Ubiquitin-Like Modifier Activating Enzyme, Refractory, Mri, Biomarker, Autoimmune Myopathy, Jak Inhibitor, Idiopathic Inflammatory Myopathies, IBM, Future, Cancer, IMNM, Anti-Mda5, Disease Activity, Seasonality

Recent Experience

- **Recruitment status :** Recruiting for NCT04972760
- **Related Drugs :** Ruxolitinib, Baricitinib
- **Related Conditions :** Myositis, Dermatomyositis
- **Population Investigated :** Adults (16-64 years old)

1 related Clinical Trial

- **June 14th, 2021** : Baricitinib in Patients With Relapsing or naïve Dermatomyositis

6 related PMC/Medline publications

🌐 Eunyoung Lee

Expert Profile



- **Position** : MD
- **Affiliations** :
 - Seoul National University Hospital and College of Medicine, Department of Internal Medicine, Division of Rheumatology, Seoul, South Korea
- **Associated Keywords** :Mitochondria

Recent Experience

- **Related Drugs** : PN-101
- **Related Conditions** : Dermatomyositis, Polymyositis
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **July 1st, 2021** : Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Eunyoung Lee hasn't contributed to any PMC/Medline publication as a main author

🌐 Daehyun Yoo

Expert Profile



- **Position** : MD
- **Affiliations** :
 - Seoul National University Hospital and College of Medicine, Department of Internal Medicine, Division of Rheumatology, Seoul, South Korea
- **Associated Keywords** :Mitochondria

Recent Experience

- **Related Drugs** : PN-101
- **Related Conditions** : Dermatomyositis, Polymyositis
- **Population Investigated** : Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **July 1st, 2021** : Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Daehyun Yoo hasn't contributed to any PMC/Medline publication as a main author

🌐 Hyunsook Kim

Expert Profile



- **Position :** MD
- **Affiliations :**
 - Seoul National University Hospital and College of Medicine, Department of Internal Medicine, Division of Rheumatology, Seoul, South Korea
- **Associated Keywords :** Mitochondria

Recent Experience

- **Related Drugs :** PN-101
- **Related Conditions :** Dermatomyositis, Polymyositis
- **Population Investigated :** Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **July 1st, 2021 :** Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Hyunsook Kim hasn't contributed to any PMC/Medline publication as a main author

Judith A James



Expert Profile

- **Position :** MD
- **Affiliations :**
 - Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Research Program, Oklahoma City, United States
- **Associated Keywords :** Suboptimal Response To Covid-19 Vaccination, Booster Effects With Autoimmune Treatments, Juvenile, Lupus Erythematosus, Systemic, Scleroderma, Vaccines, Immunosuppressive Agents

Recent Experience

- **Related Drugs :** Sanofi-GSK COVID-19 Vaccine, Elasomeran, mAbs targeting CD19 or CD20, Withhold IS (B cell depletion therapy), Mycophenolate Mofetil, COVID-19 vaccine and Bivalent, Withhold IS (MTX), SARS-CoV-2 RNA vaccine, Continue IS (MMF or MPA), Continue IS (MTX), Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Tozinameran, anti-BAFF mAb, JNJ-78436735, MMF, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, COVID-19 vaccine, Methotrexate, mycophenolic acid, Continue IS (B cell depletion therapy), Withhold IS (MMF or MPA), Ad26.COVS.2, MTX, MPA, immunosuppressive medication
- **Related Conditions :** Sclerosis, Arthritis, Rheumatoid, COVID-19, Multiple Sclerosis, Autoimmune Diseases, Arthritis, Juvenile, Pemphigus, Arthritis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated :** Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **August 6th, 2021 :** COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Judith A James hasn't contributed to any PMC/Medline publication as a main author

Meggan C Mackay



Expert Profile

- **Position :** MD
- **Affiliations :**

- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, New York, United States
- **Associated Keywords** : Suboptimal Response To Covid-19 Vaccination, Booster Effects With Autoimmune Treatments, Juvenile, Lupus Erythematosus, Systemic, Scleroderma, Vaccines, Immunosuppressive Agents

Recent Experience

- **Related Drugs** : Sanofi-GSK COVID-19 Vaccine, Elasomeran, mAbs targeting CD19 or CD20, Withhold IS (B cell depletion therapy), Mycophenolate Mofetil, COVID-19 vaccine and Bivalent, Withhold IS (MTX), SARS-CoV-2 RNA vaccine, Continue IS (MMF or MPA), Continue IS (MTX), Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Tozinameran, anti-BAFF mAb, JNJ-78436735, MMF, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, COVID-19 vaccine, Methotrexate, mycophenolic acid, Continue IS (B cell depletion therapy), Withhold IS (MMF or MPA), Ad26.COV2.S, MTX, MPA, immunosuppressive medication
- **Related Conditions** : Sclerosis, Arthritis, Rheumatoid, COVID-19, Multiple Sclerosis, Autoimmune Diseases, Arthritis, Juvenile, Pemphigus, Arthritis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated** : Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **August 6th, 2021** : COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Meggan C Mackay hasn't contributed to any PMC/Medline publication as a main author

 Dinesh Khanna

Expert Profile



- **Affiliations** :
 - Department of Dermatology, University of Michigan, Department of Rheumatology, Michigan, United States
- **Associated Keywords** : Suboptimal Response To Covid-19 Vaccination, Booster Effects With Autoimmune Treatments, Juvenile, Lupus Erythematosus, Systemic, Scleroderma, Vaccines, Immunosuppressive Agents

Recent Experience

- **Related Drugs** : Sanofi-GSK COVID-19 Vaccine, Elasomeran, mAbs targeting CD19 or CD20, Withhold IS (B cell depletion therapy), Mycophenolate Mofetil, COVID-19 vaccine and Bivalent, Withhold IS (MTX), SARS-CoV-2 RNA vaccine, Continue IS (MMF or MPA), Continue IS (MTX), Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Tozinameran, anti-BAFF mAb, JNJ-78436735, MMF, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, COVID-19 vaccine, Methotrexate, mycophenolic acid, Continue IS (B cell depletion therapy), Withhold IS (MMF or MPA), Ad26.COV2.S, MTX, MPA, immunosuppressive medication
- **Related Conditions** : Sclerosis, Arthritis, Rheumatoid, COVID-19, Multiple Sclerosis, Autoimmune Diseases, Arthritis, Juvenile, Pemphigus, Arthritis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated** : Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **August 6th, 2021** : COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Dinesh Khanna hasn't contributed to any PMC/Medline publication as a main author

 Virginia Pascual

Expert Profile



- **Position** : MD

- **Affiliations :**
 - Drukier Institute for Children's Health, Weill Cornell Medical College, Cornell, United States
 - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical College, Department of Pediatrics, New York, United States
- **Associated Keywords :** Scleroderma, Lupus Erythematosus, Vaccines, Systemic, Suboptimal Response To Covid-19 Vaccination, Juvenile, Booster Effects With Autoimmune Treatments, Immunosuppressive Agents

Recent Experience

- **Related Drugs :** Sanofi-GSK COVID-19 Vaccine, Elasmomeran, mAbs targeting CD19 or CD20, immunosuppressive medication, Mycophenolate Mofetil, Withhold IS (B cell depletion therapy), COVID-19 vaccine and Bivalent, Withhold IS (MTX), SARS-CoV-2 RNA vaccine, Continue IS (MMF or MPA), Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Tozinameran, anti-BAFF mAb, JNJ-78436735, MMF, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, COVID-19 vaccine, Methotrexate, mycophenolic acid, Continue IS (B cell depletion therapy), Withhold IS (MMF or MPA), Ad26.COV2.S, MTX, MPA, Continue IS (MTX)
- **Related Conditions :** Sclerosis, Arthritis, Rheumatoid, COVID-19, Multiple Sclerosis, Autoimmune Diseases, Arthritis, Juvenile, Pemphigus, Arthritis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated :** Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **August 6th, 2021 :** COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

1 related PMC/Medline publication

 Stacy P Ardoin

Expert Profile



- **Position :** MD
- **Affiliations :**
 - Nationwide Children's Hospital and , The Ohio State University, Department of Pediatrics, Division of Rheumatology, Columbus, United States
 - Boston Children's Hospital, Computational Health Informatics Program, Division of Immunology, Boston, United States
- **Associated Keywords :** Scleroderma, Lupus Erythematosus, Outcome Measure, Juvenile Dermatomyositis, Pediatrics, Mycophenolic Acid, Vaccines, Systemic, Suboptimal Response To Covid-19 Vaccination, Juvenile Idiopathic Arthritis, Booster Effects With Autoimmune Treatments, Immunosuppressive Agents, Childhood-Onset Lupus

Recent Experience

- **Related Drugs :** Sanofi-GSK COVID-19 Vaccine, Elasmomeran, mAbs targeting CD19 or CD20, Mycophenolate Mofetil, Withhold IS (B cell depletion therapy), COVID-19 vaccine and Bivalent, Withhold IS (MTX), SARS-CoV-2 RNA vaccine, Continue IS (MMF or MPA), Continue IS (MTX), Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Tozinameran, anti-BAFF mAb, JNJ-78436735, MMF, SARS-cov-2 (covid-19) ad26 vaccine, recombinant, COVID-19 vaccine, Methotrexate, mycophenolic acid, Continue IS (B cell depletion therapy), Withhold IS (MMF or MPA), Ad26.COV2.S, MTX, MPA, immunosuppressive medication
- **Related Conditions :** Sclerosis, Arthritis, Rheumatoid, Vasculitis, COVID-19, Multiple Sclerosis, Autoimmune Diseases, Arthritis, Juvenile, Pemphigus, Arthritis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated :** Pediatrics (2-12 years old), Adolescents (13-15 years old), Adults (16-64 years old), Senior Adults or Elders (65+ years old)

1 related Clinical Trial

- **August 6th, 2021 :** COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

1 related PMC/Medline publication

Latika Gupta

Expert Profile



- **Affiliations :**
 - Sanjay Gandhi Postgraduate Institute of Medical Sciences, Department of Clinical Immunology and Rheumatology, Lucknow, India
 - SGPGIMS, Department of Clinical Immunology and Rheumatology, Lucknow, India
 - Royal Wolverhampton Hospitals NHS Trust, Department of Rheumatology, Wolverhampton, United Kingdom
- **Contacts :** drlatikagupta@gmail.com
- **Associated Keywords :** Idiopathic Inflammatory Myositis, Juvenile Dermatomyositis, Tele-Triage, Anti-Mda5 Antibodies, Damage, Whole Genome Sequencing, Statin Induced Myositis, Vascular Health, Myositis-Specific Antibody, Connective Tissue Diseases, Myositis-Specific Autoantibodies, Hereditary Myopathy, Myopathies, Retina, Immunosuppression, Resistance Training, Autoantibody, Renal, Mortality, Biomarker, Aerobic Exercise, Interstitial Lung Disease, Idiopathic Inflammatory Myopathy, Outcomes, Myasthenia, Immunosuppressants, Immunopathogenesis, Cardiovascular, Paediatric Rheumatology, Vaccination, Cohort Studies, Cardiac, Indian Cohort, Infections, Genetic Predisposition, Telemedicine, Anti-Hmgcr Antibody, Vasculopathy, Heart, Phenotype, Treatment Outcome

Recent Experience

- **Related Drugs :** Tofacitinib, Coenzyme A, Statin
- **Related Conditions :** Myositis, Calcinosis, Rhabdomyolysis, COVID-19, Autoimmune Diseases, Autoimmunity, Panniculitis, Dermatomyositis
- **Investigated Biological Markers :** Retinaldehyde
- **Population Investigated :** Adults (16-64 years old)

19 related PMC/Medline publications (latest 5 below)

- **June 22nd, 2023 :** Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
- **May 6th, 2023 :** Cardiovascular manifestations in idiopathic inflammatory myopathies
- **February 19th, 2023 :** Reply to "Letter to the Editor Regarding 'COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis'"
- **November 30th, 2022 :** Retinal changes in patients with idiopathic inflammatory myopathies: A case-control study in the MyoCite cohort
- **September 30th, 2022 :** Panniculitis as the Transformed Cutaneous Manifestation of Refractory Dermatomyositis with Successful Management with Tofacitinib

Latika Gupta hasn't contributed to any clinical trial as an investigator

Victoria P Werth

Expert Profile



- **Affiliations :**
 - University of Pennsylvania, Department of Dermatology, Philadelphia, United States
 - Veterans Affairs Medical Center, Department of Dermatology, Philadelphia, United States
 - VAMC, Philadelphia, United States
- **Contacts :** werth@pennmedicine.upenn.edu
- **Associated Keywords :** Systemic Lupus Erythematosus, Cb2R, Autoimmune Skin Disease, Assessment Tool, Connective Tissue Disease, Lenabasum, Amyopathic, Exosomes, Infections, Extracellular Vesicles, Triggers, Ultraviolet Irradiation (Uv Irradiation), Cutaneous Lupus Erythematosus, Intravenous Immunoglobulin, Skin-Predominant, Air Pollution, Dsdna, Dendritic Cells (Dcs), Herbal Supplements, Cutaneous Dermatomyositis Disease Area And Severity Index, Stimulator Of Interferon Genes, Dermatomyositis (Dm), Microvesicles, Practice, Microparticles, Interface Dermatitis (Id), Dm, Rheumatologic Dermatology, Multidisciplinary Collaboration, Interferon-Beta (Ifn-Beta), Mxa, Criteria, Medical Dermatology, Classification, Computed Tomography, Diagnosis, Type I Interferon, Image Mass

Cytometry, Spongiotic Dermatitis (Sd), Inflammatory Myopathy, Cost Efficacy, Cutaneous Symptom, Drugs, Ifn-B, Quality Of Life

Recent Experience

- **Related Drugs** : Hydroxychloroquine, Interferon beta, CPL-7075, O-desulfated heparin
- **Related Conditions** : Myositis, Lupus Erythematosus, Cutaneous, Autoimmune Diseases, Eczema, Erythromelalgia, Lupus Erythematosus, Systemic, Dermatomyositis, Dermatitis

18 related PMC/Medline publications (latest 5 below)

- **February 6th, 2024** : Extracellular Vesicles in the Pathogenesis, Clinical Characterization, and Management of Dermatomyositis: A Narrative Review
- **October 14th, 2023** : Overlap of dermatomyositis and cutaneous lupus erythematosus: A case series
- **October 2nd, 2023** : Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study
- **July 19th, 2023** : A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis.
- **April 16th, 2023** : The physical and emotional impact of cutaneous dermatomyositis: a qualitative study.

Victoria P Werth hasn't contributed to any clinical trial as an investigator

🇯🇵 Manabu Fujimoto

Expert Profile



- **Affiliations** :
 - Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Department of Dermatology, Osaka, Japan
 - Department of Dermatology, Osaka University Graduate School of Medicine, Department of Diagnostic Pathology, Osaka, Japan
 - Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Department of Dermatology, Suita, Japan
 - Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan
- **Associated Keywords** :Anti-Tif1G Antibody, Cancer-Associated Myositis, CDASI, Tnf Receptor Superfamily, Parameter, BAFF

Recent Experience

- **Related Drugs** : Prednisolone, Azathioprine
- **Related Conditions** : Myositis, Exanthema, Myocarditis, Dermatomyositis, Melanoma, Lymphoma, T-Cell, Antisynthetase syndrome

11 related PMC/Medline publications (latest 5 below)

- **July 12th, 2023** : Dermatomyositis
- **May 10th, 2023** : A Combination of Autoantibodies Predicts the Fate of Cancer-Associated Dermatomyositis.
- **July 8th, 2022** : Erratum to "Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1g antibodies" [J. Dermatol. Sci. 104 (2021) 177-84
- **January 3rd, 2022** : Myxovirus resistance protein 1-expressing fatal myocarditis in a patient with anti-MDA5 antibody-positive dermatomyositis.
- **November 28th, 2021** : Case of anti-Mi-2 antibody-positive dermatomyositis with predictable onset before the development of muscle symptoms.

Manabu Fujimoto hasn't contributed to any clinical trial as an investigator

🇨🇳 Guochun Wang

Expert Profile



- **Affiliations :**
 - China-Japan Friendship Hospital, Department of Rheumatology, Beijing, China
 - Department of Neurology, Peking University First Hospital, Department of Rheumatology, Beijing, China
 - Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China
- **Contacts :** guochunwang@hotmail.com
- **Associated Keywords :** Idiopathic Inflammatory Myopathies, Cohort Study, Treatment, Adult, Clinical Characteristics, Outcome, Anti-Mda5 Antibody, Infection, Interstitial Lung Disease, Risk Factors, Skin Lesion, Prognosis, Thromboembolic Events, Dermatomyositis, Pneumomediastinum

Recent Experience

- **Related Drugs :** Tofacitinib, Infliximab, Rituximab
- **Related Conditions :** Myositis, Calcinosis, Melanoma, Dermatomyositis, Mediastinal Emphysema
- **Population Investigated :** Adults (16-64 years old)

9 related PMC/Medline publications (latest 5 below)

- **January 3rd, 2024 :** Spontaneous pneumomediastinum in anti-MDA5-positive dermatomyositis: Prevalence, risk factors, and prognosis.
- **December 6th, 2023 :** Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.
- **July 26th, 2023 :** Efficacy and Safety of Tofacitinib in Anti-Melanoma Differentiation-Associated 5 Gene Antibody-Positive Dermatomyositis.
- **August 30th, 2022 :** Biomarkers of disease activity in dermatomyositis.
- **April 11th, 2022 :** Thromboembolic events in idiopathic inflammatory myopathy: a retrospective study in China.

Guochun Wang hasn't contributed to any clinical trial as an investigator

Yongpeng Ge

Expert Profile



- **Affiliations :**
 - China-Japan Friendship Hospital, Department of Rheumatology, Beijing, China
- **Associated Keywords :** Idiopathic Inflammatory Myopathies, Anti-Mda5 Antibody, Pneumocystis Jirovecii Pneumonia, Myositis Specific Autoantibodies, DM, Health Services For The Aged, Hemophagocytic Syndrome, Infliximab, Epidemiology, Interstitial Lung Disease, Sars-Cov-2 Vaccine, Hospitalization, Skin Lesion, Opportunistic Infections, Rheumatology, Outcomes, Anti-Aminoacyl-Trna Synthetase, Inflammatory Myopathy, Dermatomyositis, Coronavirus Disease 2019 Vaccine, Anti-Melanoma Differentiation-Associated Gene 5 Antibody, Prevalence, Metagenomic Next-Generation Sequencing

Recent Experience

- **Related Drugs :** Intedanib, Rituximab, Infliximab
- **Related Conditions :** Macrophage Activation Syndrome, Pneumonia, Pneumocystis, Myositis, Calcinosis, Arthritis, Rheumatoid, Gastroesophageal Reflux, Mixed Connective Tissue Disease, COVID-19, Lymphohistiocytosis, Hemophagocytic, Melanoma, Dermatomyositis

9 related PMC/Medline publications (latest 5 below)

- **May 13th, 2024 :** Interstitial Lung Disease in Patients with Mixed Connective Tissue Disease: A Retrospective Study
- **December 27th, 2023 :** Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease.
- **November 24th, 2023 :** Geospatial analysis of the hospitalisation rate of patients with rheumatoid arthritis in Hunan: a cross-sectional Chinese study
- **October 5th, 2023 :** High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis.
- **October 21st, 2022 :** Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic review

Yongpeng Ge hasn't contributed to any clinical trial as an investigator

🇨🇦 Brian M Feldman



Expert Profile

- **Position** : MD
- **Affiliations** :
 - The Hospital for Sick Children, Department of Pediatrics, Division of Rheumatology, Ontario, Canada
 - The Hospital for Sick Children, Department of Pediatrics, and Department of Rehabilitation, Division of Rheumatology, Whitney, United States
 - Hospital for Sick Children Research Institute, Ontario, Canada
 - SickKids Research Institute, Child Health Evaluative Sciences Program, Toronto, Canada
- **Contacts** : brian.feldman@sickkids.ca
- **Associated Keywords** :Treatment Outcome, Cutaneous Dermatomyositis Disease Area And Severity Index (Cdasi), Juvenile Dermatomyositis, Cutaneous Assessment Tool (Cat), Wingate Anaerobic Test, Gottron'S Sign/Papules, Stress Reaction, Complication, Mmt Manual Muscle Testing, Registries, Creatine, Physical Therapy, Heliotrope Rash, Physician'S Global Assessment Skin Visual Analog Scale (Skin Vas), Feasibility, Magnetic Resonance Spectroscopy, Stress Fracture, Randomized Controlled Trial, Chaq Child Health Assessment Questionnaire, Pediatric Rheumatology, Tibia, Autoimmune Disease, Patient Outcomes, Cohort Studies, Exercise Test, Disease Activity Score Skin Subscale (Skindas), Risk Factors

Recent Experience

- **Related Drugs** : Creatine ALS-08
- **Related Conditions** : Myositis, Calcinosis, Polymyositis, Exanthema, Autoimmune Diseases, Dermatomyositis
- **Population Investigated** : Pediatrics (2-12 years old)

8 related PMC/Medline publications (latest 5 below)

- **June 28th, 2023** : Currently recommended skin scores correlate highly in the assessment of patients with Juvenile Dermatomyositis (JDM)
- **September 25th, 2022** : The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
- **August 1st, 2022** : Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis.
- **March 28th, 2022** : Feasibility of the wingate anaerobic exercise test as a clinical measure in patients with juvenile dermatomyositis
- **February 17th, 2021** : Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences

Brian M Feldman hasn't contributed to any clinical trial as an investigator

🇯🇵 Tsutomu Takeuchi



Expert Profile

- **Affiliations** :
 - Keio University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Tokyo, Japan
 - Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Division of Central Laboratory, Osaka, Japan
 - Osaka Medical and Pharmaceutical University, Department of Internal Medicine, Division of Rheumatology, Takatsuki, Japan
 - Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan
- **Associated Keywords** :Interstitial Lung Disease, Systemic Lupus Erythematosus, Polymyositis-Dermatomyositis, Multidetector Computed Tomography, Connective Tissue Disease, Chemokines, Macrophages, Pulmonary Fibrosis, S100, Immunosuppressive Therapy, Anti-Mda5 Antibody, Cd4-Positive T Cells, Thymus Gland, Sjogren'S Syndrome

Recent Experience

- **Related Drugs** : Tofacitinib, Bleomycin, O-desulfated heparin
- **Related Conditions** : Myositis, Fibrosis, COVID-19, Autoimmune Diseases, Melanoma, Pulmonary Fibrosis, Lupus Erythematosus, Systemic, Dermatomyositis
- **Population Investigated** : Adults (16-64 years old)

8 related PMC/Medline publications (latest 5 below)

- **March 6th, 2024** : Cytotoxic Tph subset with low B-cell helper functions and its involvement in systemic lupus erythematosus
- **December 8th, 2023** : Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
- **October 6th, 2022** : Thymus variants on imaging of patients with primary Sjogren's syndrome and polymyositis/dermatomyositis: clinical and immunological significance.
- **September 8th, 2022** : Comment on: Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
- **August 26th, 2022** : Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease

Tsutomu Takeuchi hasn't contributed to any clinical trial as an investigator

 **Adrian Y S Lee**

Expert Profile



- **Affiliations** :
 - Westmead Hospital, Wales, Australia
- **Associated Keywords** : Adult-Onset Still's Disease, Immunology, Overlap Myositis, Neurology, Mesenchymal Stem Cell, Rheumatology, Clinical Features, Antineutrophil Cytoplasmic Antibody, Immunomodulation, Atypical Type Of Skin Rash, Mitochondria, Novel Classification Criteria, Idiopathic Inflammatory Myositis, Interstitial Lung Disease, Fever, Myositis Specific Autoantibody, Adult Dermatology, Anti-Synthetase Syndrome, Persistent Dermal Plaque, Mortality, Dyskeratotic Cell, Persistent Pruritic Eruptions, Apoptosis, Horny Layer

Recent Experience

- **Related Drugs** : Tozinameran
- **Related Conditions** : Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Myositis, Vasculitis, COVID-19, Exanthema, Polymyositis, Pulmonary Fibrosis, Dermatomyositis
- **Population Investigated** : Adults (16-64 years old)

7 related PMC/Medline publications (latest 5 below)

- **December 11th, 2023** : Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms
- **October 25th, 2023** : Overlap Syndrome Consisting of Polymyositis/Dermatomyositis and ANCA-Associated Vasculitis According to the 2022 ACR/EULAR Criteria for Vasculitis: A Korean Single-Centre Study
- **June 12th, 2023** : Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination.
- **May 15th, 2023** : A Case of Multiple Necrotic Dyskeratotic Cells within the Upper Epidermis and Horny Layer Revealing Persistent Papules and Plaques of Adult-Onset Still's Disease
- **April 6th, 2022** : Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis

Adrian Y S Lee hasn't contributed to any clinical trial as an investigator

 **Jian Qiang Lu**

Expert Profile



- **Affiliations** :
 - McMaster University, Department of Pathology and Molecular Medicine, Ontario, Canada

- **Contacts** : jlu@uchc.edu
- **Associated Keywords** : Interstitial Lung Disease, Clinical Trials, Clinically Amyopathic Dermatomyositis, Scleroderma, Palmar Papules, Skin Manifestations, Neurogenic Myopathy, Autoimmune Disease, Concentric Cristae, Mitochondria, Cylindrical Spirals, Concentric Laminated Bodies, Neuromuscular Disorders, Systemic Sclerosis, Palmar Erythema

Recent Experience

- **Related Conditions** : Erythema, Amyopathic dermatomyositis, Sarcoidosis, Autoimmune Diseases, Scleroderma, Systemic, Dermatomyositis

7 related PMC/Medline publications (latest 5 below)

- **October 31st, 2023** : Ocular and eyelid involvement in collagen vascular diseases. Part II. Dermatomyositis, scleroderma, and sarcoidosis.
- **July 16th, 2023** : Cylindrical spirals and other concentric structures of skeletal muscle in patients with neurological diseases.
- **February 22nd, 2022** : Palmar erythema and palmar papules as predictors for dermatomyositis-related acute/subacute interstitial lung disease: a retrospective study.
- **February 22nd, 2022** : Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma.
- **October 26th, 2021** : Nutrition and connective tissue disease.

Jian Qiang Lu hasn't contributed to any clinical trial as an investigator

 **Masataka Kuwana**

Expert Profile



- **Position** : MD
- **Affiliations** :
 - Nippon Medical School, Department of Allergy and Rheumatology, Tokyo, Japan
 - Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Moldova
 - Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Okazaki, Japan
- **Contacts** : kuwanam@nms.ac.jp
- **Associated Keywords** : Autoimmune Rheumatic Disorders, Anti-Mda5 Antibodies, Follicular Dendritic Cells, B Cells, Tertiary Lymphoid Structure, Tumor-Infiltrating Lymphocyte, Myositis-Specific Autoantibodies, Interstitial Lung Disease, Cancer, Scleroderma, Immunoprecipitation, Postmarketing Product Surveillance, Anti-Ro52 Antibodies, Anti-Synthetase Syndrome, Cluster Analysis, Immunoblot, Immunosuppressive Agent, Enzyme-Linked Immunosorbent Assay, Follicular Helper T Cell

Recent Experience

- **Related Drugs** : Tacrolimus
- **Related Conditions** : Myositis, Dermatomyositis, Polymyositis, Pneumonia

7 related PMC/Medline publications (latest 5 below)

- **April 8th, 2024** : Clinical phenotyping in patients with anti-synthetase antibodies using cluster analysis
- **December 8th, 2023** : Dissociating Autoantibody Responses against Ro52 Antigen in Patients with Anti-Synthetase or Anti-MDA5 Antibodies
- **April 17th, 2023** : A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting.
- **January 4th, 2023** : Tertiary lymphoid structures in the primary tumor site of patients with cancer-associated myositis: A case-control study
- **April 15th, 2022** : Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan.

Masataka Kuwana hasn't contributed to any clinical trial as an investigator

Annex:

Technology and Report Usage

Disclaimer

This report is a statistical analysis focused on researchers and investigators active in the specified therapeutic area/ Pathology. It aims to highlight current contributors who are actively publishing on this subject. Please note the following key points:

1. Data Scope

This report exclusively includes data from research publications and does not cover information from congresses, workshops, speeches, or other non-publication events.

2. Time Frame

The analysis covers publications within a specific time frame. Consequently, well-known contributors in the field may not be mentioned if their contributions fall outside this period. The objective is to assess current and effective sites and researchers, rather than those with established reputations.

3. Authorship

The statistics in this report focus solely on first and last authors within the publications. The names of middle authors are listed in the "Middle Authors" column in the "Publication" sheet.

4. Affiliations

Researchers may have been affiliated with multiple institutions throughout their careers. The actual affiliation could be based on the affiliation of the most recent publication.

Practical Guidance: Excel Sheets

This report is based on data extracted and presented in an Excel format. The accompanying Excel sheet, provided with this PDF, includes three main sheets, each serving a specific purpose:

Publication Sheet

This sheet contains comprehensive metrics about articles or clinical trials published within the specified time frame. It links these publications to corresponding affiliations/sites and authors/investigators. This information is essential for understanding the context and scope of the research covered in this report.

Affiliation Sheet

The "Affiliation" sheet provides detailed information and metrics related to the affiliations involved. It includes standardized names, countries, sponsors, collaborators, investigated drugs, associated keywords, publications, and the authors/investigators affiliated with each institution. This sheet helps users to identify and analyze the roles of different institutions in the research landscape.

Authors Sheet

The "Authors" sheet lists the authors and investigators involved in the specific subject of this report. It includes detailed information on their profiles, such as affiliations, contact details, associated keywords, recent experiences, and important publications related to the subject. This sheet is designed to offer insights into the key contributors and their research contributions.

In order to help you better understand the informations and statistics provided with this report, you can find here small explanations and tips for each section or subsection

Global / Local Insights : Top Affiliations

Within this section, you will find the top 10 affiliations (worldwide + in a specific continental zone or in a specific country) based on the number of clinical trials conducted in these affiliations/sites, excluding affiliations directly related to a pharmaceutical company. However, these affiliations are still included in the CSV file.

Main Key Contributors

This section identifies the top five most prestigious and cited key contributors associated with a specific affiliation. The ranking prioritizes professors, followed by medical directors, doctors, PhDs, PharmDs, and lastly, associate professors.

Note : It's possible that no Key Contributors are identified for an affiliation even if clinical trials (CTs) were conducted within it. This could indicate that the investigator named in the CT is linked to a different affiliation that was involved in the trial.

Main Recruiting Clinical Trials

Within this section, you will find all the clinical trials that are currently recruiting for the requested pathology in this specific affiliation. For each clinical trial, we provide details including the sponsor name, collaborator name, investigator name, drugs and conditions investigated, the number of patients enrolled, and the trial duration if available.

Recent but Not Recruiting Clinical Trials

Within this section, you will find all the clinical trials for the requested pathology in this specific affiliation that are recent (less than 5 years old) but are not currently recruiting, which could indicate they have either been completed or have not yet started. For each clinical trial, we provide details including the sponsor name, collaborator name, investigator name, drugs and conditions investigated, the number of patients enrolled, and the trial duration if available.

Global / Local Insights : Top Key Contributors for Clinical Trials / Pubmed

Within this section, you will find the top 10 Key Contributors (worldwide + in a specific continental zone or in specific countries) based on the number of clinical trials in which they participated as investigators. For PubMed, the top 10 ranking is determined by the number of publications where they are listed as first and/or last authors.

Expert Profile

In this section, we aim to summarize the profile of the author/investigator by analyzing patterns such as their position, affiliations, contacts, and keywords provided by them. This helps to encapsulate their expertise within the field effectively.

X related Clinical Trials / Publications

In this section, users will find a summary of the clinical trials or publications in which the author/investigator has contributed. This summary includes information about the drugs, populations, and biomarkers investigated. Additionally, we mention whether the investigator is currently recruiting for a clinical trial or not.

5 last Clinical Trials / Publications

This section highlights the five most recent publications or clinical trials contributed by the Key Contributor. The aim is to showcase their recent activity in terms of topics and frequency, providing insights into their current research focus and engagement within the field.

Technologies Used

To provide transparency about the technology behind this report and ensure you can effectively interpret the results, the ArcaScience team has included a brief explanation of the tools/technologies used in its generation.

Data Source and Extraction Methodology

- **Data Source** : This report utilizes data from ClinicalTrials.Gov, PMC, and Medline and extracts data based on specific conditions and specific timeframe.
- **Extraction Methodology** : A double-phased extraction process based on an accurate pathology ontology was employed (Used on document metadata, then on population text patterns).

AI-Powered Data Harmonization

Data harmonization bridges inconsistencies across various sources, leading to a more cohesive and trustworthy analysis.

Here's a breakdown of the key data points harmonized:

- **Author/Investigator Names** : Multi-stage AI model approach to optimize the identification and standardization of author/investigator names. This process ensures consistent representation and avoids duplicates.
- **Affiliation Names** : Our models were optimized to recognize and group affiliations across various categories. This not only eliminates duplicates but also allows for clustering affiliations and linking them to specific countries, even if not explicitly mentioned.
- **Investigated Population Characteristics** : Extraction and Standardization of various patient characteristics, including age, gender, underlying conditions, ethnicity, and other relevant demographic information.
- **Interventions** : Harmonized using a well-developed and up-to-date drug ontology to ensure consistent representation and categorization of interventions used in the analyzed trials.
- **Additional Extracted Data Points** : In addition to the core elements mentioned above, our comprehensive approach extracts and harmonizes a wider range of data points to enrich the analysis. These include: Author Position in Publication, Journals of Publication, Number of Patients Enrolled, Trial Duration and many other data points.

At the end of this step, publications, key contributors, and affiliations were linked based on the AI harmonization results.

Data Enrichment

By leveraging the established relationships and links, we utilize our developed ontologies and AI to associate keywords and tags with each contributor. These tags highlight their expertise and experience based on their publication history and affiliations.

Insights Generation

Within this step, we prioritize providing a comprehensive set of metrics and information to empower customers in evaluating affiliations and authors within the report. This allows them to make the most informed decisions. To achieve this, we generate diverse statistics for analysis.

Quality Control

To guarantee the reliability of our analysis, we employ a sampling validation process. This process verifies the accuracy of key data points, including: Condition accuracy, Affiliation harmonization, Key Contributors harmonization and Tagging processes. The final PDF undergoes a manual validation by our in-house Pharma Expert.